Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Paroxetine Mesylate

FDA-approved product (tablet, oral), marketed as Paroxetine, Paroxetine Hydrochloride, Paxil and 4 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Paroxetine Mesylate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Anxiety disorder
  • Depressive disorder
  • Major depressive disorder
  • Menopause
  • Obsessive-compulsive disorder
  • Panic disorder
  • Post-traumatic stress disorder
  • Social anxiety disorder

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Selective serotonin reuptake inhibitors
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA39.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli23.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae19.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis58.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Paroxetine Mesylate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.3 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.1 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.6 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.7 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Paroxetine Mesylate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Long-term Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy in Patients With Major Depressive Disorder

    NCT01838876 · start 2013-04-29

    Registered record
    Registry ID
    NCT01838876
    Conditions
    Major Depressive Disorder
    Interventions
    Cariprazine; Antidepressant Therapy (ADT)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2013-04-29
    Completion
    2015-07-27
    Enrolment
    442

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMajor Depressive Disorder
    InterventionCariprazine; Antidepressant Therapy (ADT)
    PhasePhase 3
    Registry statusCompleted

  • Newer Antidepressants in Combination With Pregabalin for Fibromyalgia Syndrome

    NCT02451475 · start 2013-02

    Registered record
    Registry ID
    NCT02451475
    Conditions
    Fibromyalgia
    Interventions
    Amitriptyline; Venlafaxine; Paroxetine
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2013-02
    Completion
    2014-10
    Enrolment
    75

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFibromyalgia
    InterventionAmitriptyline; Venlafaxine; Paroxetine
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)

    NCT01715805 · start 2012-11-15

    Registered record
    Registry ID
    NCT01715805
    Conditions
    Major Depressive Disorder
    Interventions
    Cariprazine; Placebo; Antidepressant Therapy (ADT)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2012-11-15
    Completion
    2016-06-24
    Enrolment
    1,022

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMajor Depressive Disorder
    InterventionCariprazine; Placebo; Antidepressant Therapy (ADT)
    PhasePhase 3
    Registry statusCompleted

  • Vilazodone for Treatment of Geriatric Depression

    NCT01608295 · start 2012-07

    Registered record
    Registry ID
    NCT01608295
    Conditions
    Major Depressive Disorder
    Interventions
    Vilazodone; Viibryd; Paroxetine; Paxil
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2012-07
    Completion
    2015-09
    Enrolment
    65

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMajor Depressive Disorder
    InterventionVilazodone; Viibryd; Paroxetine; Paxil
    PhasePhase 4
    Registry statusCompleted

  • A Paroxetine- and Placebo-Controlled Study of 50 mg/Day and 100 mg/Day of EB-1010 Among Outpatients With Major Depressive Disorder Who Have Responded Inadequately to Prior Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin Norepinephrine Reuptake Inhibitors (SNRIs)

    NCT01318434 · start 2011-02

    Registered record
    Registry ID
    NCT01318434
    Conditions
    Major Depressive Disorder
    Interventions
    EB-1010 25mg BID; SSRI Active; EB-1010 50mg BID; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2011-02
    Completion
    2013-02
    Enrolment
    342

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMajor Depressive Disorder
    InterventionEB-1010 25mg BID; SSRI Active; EB-1010 50mg BID; Placebo
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • Adjunctive Mixed Salts Amphetamine for Depressed Adults With Incomplete Response to Current Antidepressant Therapy

    NCT02058693 · start 2010-12

    Registered record
    Registry ID
    NCT02058693
    Conditions
    Major Depressive Disorder
    Interventions
    mixed salts amphetamine
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2010-12
    Completion
    2014-12
    Enrolment
    41

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMajor Depressive Disorder
    Interventionmixed salts amphetamine
    PhasePhase 4
    Registry statusCompleted

  • Brain Markers of Treatment Response in Post-Traumatic Stress Disorder (PTSD)

    NCT00700999 · start 2008-10

    Registered record
    Registry ID
    NCT00700999
    Conditions
    Post-traumatic Stress Disorder
    Interventions
    Paroxetine
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2008-10
    Completion
    2012-03
    Enrolment
    65

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPost-traumatic Stress Disorder
    InterventionParoxetine
    PhasePhase 4
    Registry statusCompleted

  • Study to Investigate the Effect of Paroxetine Mediated CYP2D6 Inhibition on the Pharmacokinetics of Tamsulosin in Healthy Male Volunteers

    NCT02264184 · start 2008-09

    Registered record
    Registry ID
    NCT02264184
    Conditions
    Healthy
    Interventions
    Tamsulosin; Paroxetine
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2008-09
    Completion
    Not recorded
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionTamsulosin; Paroxetine
    PhasePhase 1
    Registry statusCompleted

  • Dementia Antipsychotics And Antidepressants Discontinuation Study

    NCT00594269 · start 2008-08

    Registered record
    Registry ID
    NCT00594269
    Conditions
    Dementia
    Interventions
    Risperidone; Escitalopram; Citalopram; Sertraline; Paroxetine
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2008-08
    Completion
    2010-12
    Enrolment
    149

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDementia
    InterventionRisperidone; Escitalopram; Citalopram; Sertraline +1 more
    PhasePhase 4
    Registry statusCompleted

  • A Study Of Sertraline Compared With Paroxetine In The Treatment Of Panic Disorder

    NCT00677352 · start 2008-05

    Registered record
    Registry ID
    NCT00677352
    Conditions
    Panic Disorder
    Interventions
    sertraline; Paroxetine
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2008-05
    Completion
    2010-02
    Enrolment
    321

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPanic Disorder
    Interventionsertraline; Paroxetine
    PhasePhase 4
    Registry statusCompleted

  • An Eight-week Study of Saredutant and Paroxetine as Combination Treatment for Major Depressive Disorder

    NCT00629551 · start 2008-02

    Registered record
    Registry ID
    NCT00629551
    Conditions
    Depressive Disorder, Major
    Interventions
    saredutant (SR48968); paroxetine; placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2008-02
    Completion
    2009-02
    Enrolment
    825

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDepressive Disorder, Major
    Interventionsaredutant (SR48968); paroxetine; placebo
    PhasePhase 3
    Registry statusCompleted

  • Benefits of Switching Antidepressants Following Early Nonresponse

    NCT00519012 · start 2007-08

    Registered record
    Registry ID
    NCT00519012
    Conditions
    Depression
    Interventions
    Sertraline to Paroxetine; Paroxetine to Sertraline
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2007-08
    Completion
    2010-12
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDepression
    InterventionSertraline to Paroxetine; Paroxetine to Sertraline
    PhasePhase 4
    Registry statusUnknown

  • Vestipitant Or Vestipitant/Paroxetine Combination In Subjects With Tinnitus And Hearing Loss.

    NCT00394056 · start 2006-12

    Registered record
    Registry ID
    NCT00394056
    Conditions
    Tinnitus
    Interventions
    Vestipitant; Vestipitant + Paroxetine; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2006-12
    Completion
    2009-08
    Enrolment
    26

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTinnitus
    InterventionVestipitant; Vestipitant + Paroxetine; Placebo
    PhasePhase 2
    Registry statusCompleted

  • Treatment of Mood and Marriage Study (TOMMS)

    NCT00612807 · start 2006-07

    Registered record
    Registry ID
    NCT00612807
    Conditions
    Major Depressive Disorder; Partner Relational Disorder (V61.10)
    Interventions
    Weekly marital therapy; As indicated: Sertraline, bupropion, venlafaxine, mirtazepine, nortriptyline, tranylcypromine, lithium augmentation, etc.
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2006-07
    Completion
    2010-06
    Enrolment
    42

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMajor Depressive Disorder; Partner Relational Disorder (V61.10)
    InterventionWeekly marital therapy; As indicated: Sertraline, bupropion, venlafaxine, mirtazepine, nortriptyline, tranylcypromine, lithium augmentation, etc.
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • A Repeat Dose Pharmacokinetic Study Of Paroxetine CR Tablet In Healthy Chinese Subjects

    NCT00406432 · start 2006-05-09

    Registered record
    Registry ID
    NCT00406432
    Conditions
    Depressive Disorder
    Interventions
    Paroxetine Controlled Release Tablet
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2006-05-09
    Completion
    2006-06-02
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDepressive Disorder
    InterventionParoxetine Controlled Release Tablet
    PhasePhase 1
    Registry statusCompleted